|Rapid Review complete
|For the treatment and prevention of COVID-19.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|On the basis of current evidence, the NCPE recommends that casirivimab/imdevimab not be considered for reimbursement at this time*.
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.